Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 11—November 2026
Synopsis
Subacute Sclerosing Panencephalitis after Measles Outbreaks, the Philippines, 2007–2022
Maela P. Palisoc
, Maridel S. Ramones, and Roland Dominic G. Jamora
, Maridel S. Ramones, and Roland Dominic G. Jamora
Table
Demographic and clinical characteristics of 20 children with subacute sclerosing panencephalitis in study of subacute sclerosing panencephalitis after measles outbreaks, National Children’s Hospital, the Philippines, 2007–2022*
| Characteristic | No. patients, N = 20 |
|---|---|
| Sex | |
| M | 14 (70.0) |
| F |
6 (30.0) |
| Median age at admission, y (IQR) |
6.2 (3.8–8.4) |
| Median age at reported measles illness, y, n = 19 (IQR) |
0.7 (0.4–2.0) |
| Median duration of symptoms before admission, d (IQR) |
82 (30–128) |
| Median length of stay, d (IQR) |
10 (6–14) |
| Nutritional status | |
| No stunting, no wasting | 12 (60.0) |
| Wasted, not stunted | 5 (25.0) |
| Concurrent stunting and wasting | 2 (10.0) |
| Stunted, not wasted |
1 (5.0) |
| No comorbidity |
17 (85.0) |
| Tuberculosis |
2 (10.0) |
| Bilateral cryptorchidism |
1 (5.0) |
| Reported measles history | |
| Present | 15 (75.0) |
| Unknown | 4 (20.0) |
| Absent |
1 (5.0) |
| Vaccination | |
| Measles vaccine only | 11 (55.0) |
| Measles and MMR | 6 (30.0) |
| None |
3 (15.0) |
| Stage at admission† | |
| Stage 1 | 3 (15.0) |
| Stage 2 | 12 (60.0) |
| Stage 3 | 5 (25.0) |
| Stage 4 |
0 |
| *Values are no. (%) except as indicated. IQR, interquartile range; MMR, measles, mumps, and rubella. †Clinical stage follows the conventional description of SSPE: stage 1, behavioral and cognitive decline; stage 2, myoclonus and seizures; stage 3, extrapyramidal signs and progressive unresponsiveness; stage 4, coma or vegetative state (1,2). |
|
References
- Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29:
e2058 . DOIPubMedGoogle Scholar - Jafri SK, Kumar R, Ibrahim SH. Subacute sclerosing panencephalitis—current perspectives. Pediatric Health Med Ther. 2018;9:67–71. DOIPubMedGoogle Scholar
- Takashima Y, Schluter WW, Mariano KM, Diorditsa S, de Quiroz Castro M, Ou AC, et al.; Centers for Disease Control and Prevention (CDC). Progress toward measles elimination—Philippines, 1998–2014. MMWR Morb Mortal Wkly Rep. 2015;64:357–62.PubMedGoogle Scholar
- World Health Organization. UNICEF. WHO/UNICEF estimates of national immunization coverage: Philippines, 2025 revision [cited 2026 Jul 23]. https://worldhealthorg.shinyapps.io/wuenic-trends
- Domai FM, Agrupis KA, Han SM, Sayo AR, Ramirez JS, Nepomuceno R, et al. Measles outbreak in the Philippines: epidemiological and clinical characteristics of hospitalized children, 2016–2019. Lancet Reg Health West Pac. 2022;19:
100334 . DOIPubMedGoogle Scholar - Rabanes AC, Cruz-Urbi CM. Demographic, clinical, imaging, and EEG characteristics of subacute sclerosing panencephalitis. Eur J Paediatr Neurol. 2017;21(Suppl 1).
- Ali S, Kumar H, Ullah S, Haq MAU, Gul NG, Kumar J. Electroencephalography patterns of subacute sclerosing panencephalitis. Cureus. 2021;13:
e15728 .PubMedGoogle Scholar - Lam T, Ranjan R, Newark K, Surana S, Bhangu N, Lazenbury A, et al. A recent surge of fulminant and early onset subacute sclerosing panencephalitis (SSPE) in the United Kingdom: an emergence in a time of measles. Eur J Paediatr Neurol. 2021;34:43–9. DOIPubMedGoogle Scholar
- Pipo-Deveza JR, Kusuhara K, Silao CLT, Lukban MB, Salonga AM, Sanchez BC, et al. Analysis of MxA, IL-4, and IRF-1 genes in Filipino patients with subacute sclerosing panencephalitis. Neuropediatrics. 2006;37:222–8. DOIPubMedGoogle Scholar
- Lukban MB, Chua-Macrohon BC, Salonga AM. The use of intravenous immunoglobulin in subacute sclerosing panencephalitis: a retrospective cohort study. Acta Med Philipp. 2013;47:46–50. DOIGoogle Scholar
Page created: September 21, 2026
Page updated: October 13, 2026
Page reviewed: October 13, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.